- Home
- DTIL vs OTLK Comparison
DTIL vs OTLK Comparison
Compare DTIL & OTLK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- DTIL
- OTLK
- Stock Information
- Founded
- DTIL 2006
- OTLK 2010
- Country
- DTIL United States
- OTLK United States
- Employees
- DTIL N/A
- OTLK N/A
- Industry
- DTIL Biotechnology: Pharmaceutical Preparations
- OTLK Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- DTIL Health Care
- OTLK Health Care
- Exchange
- DTIL Nasdaq
- OTLK Nasdaq
- Market Cap
- DTIL 51.6M
- OTLK 48.3M
- IPO Year
- DTIL 2019
- OTLK 2016
- Fundamental
- Price
- DTIL $4.49
- OTLK $2.03
- Analyst Decision
- DTIL Strong Buy
- OTLK Strong Buy
- Analyst Count
- DTIL 2
- OTLK 5
- Target Price
- DTIL $47.00
- OTLK $9.60
- AVG Volume (30 Days)
- DTIL 549.2K
- OTLK 871.2K
- Earning Date
- DTIL 07-31-2025
- OTLK 08-13-2025
- Dividend Yield
- DTIL N/A
- OTLK N/A
- EPS Growth
- DTIL N/A
- OTLK N/A
- EPS
- DTIL N/A
- OTLK 0.83
- Revenue
- DTIL $51,141,000.00
- OTLK N/A
- Revenue This Year
- DTIL N/A
- OTLK N/A
- Revenue Next Year
- DTIL $53.21
- OTLK $419.06
- P/E Ratio
- DTIL N/A
- OTLK $2.50
- Revenue Growth
- DTIL N/A
- OTLK N/A
- 52 Week Low
- DTIL $3.61
- OTLK $0.87
- 52 Week High
- DTIL $11.09
- OTLK $9.25
- Technical
- Relative Strength Index (RSI)
- DTIL 54.93
- OTLK 66.41
- Support Level
- DTIL $4.08
- OTLK $1.56
- Resistance Level
- DTIL $4.38
- OTLK $2.00
- Average True Range (ATR)
- DTIL 0.28
- OTLK 0.13
- MACD
- DTIL 0.05
- OTLK 0.03
- Stochastic Oscillator
- DTIL 85.26
- OTLK 95.88
About DTIL Precision BioSciences Inc.
Precision BioSciences Inc is a genome editing company dedicated to improving life through its genome editing platform, ARCUS. It leverages ARCUS in the development of its product candidates, which are designed to treat human diseases and provide food and agricultural solutions. The ARCUS is in its relatively small size which potentially allows delivery to a wider range of cells and tissues using viral and non-viral gene delivery methods.
About OTLK Outlook Therapeutics Inc.
Outlook Therapeutics Inc is a clinical stage biopharmaceutical company focused on developing and commercializing ONS-5010, a monoclonal antibody, or mAb, for various ophthalmic indications. The Company have received marketing authorization for an ophthalmic formulation of ONS-5010/LYTENAVA (bevacizumab-gamma) for use in treating wet age-related macular degeneration, or wet AMD, in the European Union, and United Kingdom. The product pipeline includes ONS-5010/LYTENAVA which is in total eight NORSES; ONS-5010 Clinical Progress, Unmet Patient Needs, New Ophthalmic Anti-VEGF, and Potential First Line Therapy.